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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.003Genome-wide association studies have identiﬁed 72 loci associated with breast cancer susceptibility.
Seventeen of these are known to predispose to other cancers. High-penetrance susceptibility loci for
breast cancer usually result from coding alterations, principally in genes involved in DNA repair,
whereas almost all of the associations identiﬁed through genome-wide association studies are found in
noncoding regions of the genome and are likely to involve regulation of genes in multiple pathways.
However, the genes underlying most associations are not yet known. In this review, we summarize the
ﬁndings from genome-wide association studies in breast cancer and describe the genes and mechanisms
that are likely to be involved in the tumorigenesis process. We also discuss approaches to ﬁne-scale
mapping of susceptibility regions used to identify the likely causal variant(s) underlying the associa-
tions, a major challenge in genetic epidemiology. Finally, we discuss the potential impact of such
ﬁndings on personalized medicine and future avenues for screening, prediction, and prevention
programs. (Am J Pathol 2013, 183: 1038e1051; http://dx.doi.org/10.1016/j.ajpath.2013.07.003)Supported by the European Community’s Seventh Framework Programme
grant 223175 (HEALTH-F2-2009-223175) and Cancer Research UK.
This article is part of a review series on the molecular pathogenesis of breast
cancer.Introduction
Breast cancer is the most common cancer among women in
both developing and developed regions in the world,
accounting for 23% of all malignancies in women world-
wide.1 In the United States, the lifetime risk of breast cancer
is approximately one in eight.2 It is also the most common
cause of cancer-related deaths worldwide (nearly 400,000
a year).1
The incidence of breast cancer is approximately twofold
higher in ﬁrst-degree relatives of breast cancer patients. This
risk increases with the number of affected relatives and is
much greater for women with relatives affected at a young
age.3e6 The higher prevalence of breast cancer among
monozygotic twins of patients compared with dizygotic twins
or siblings suggests strongly that genetic, rather than envi-
ronmental, factors account for most of the familial aggrega-
tion. Molecular genetic studies during the past 20 years have
demonstrated that the genetic basis of susceptibility to breast
cancer is complex, and is the result of germ-line variation at
many different loci. The susceptibility alleles at these loci havestigative Pathology.
.widely different frequencies, and confer different disease risks
(Figure 1). Genetic variants for breast cancer can be broadly
categorized into high-, moderate-, and low-penetrance alleles.
The high-penetrance alleles typically confer lifetime risks of
breast cancer of >50%, sufﬁcient to warrant intervention to
reduce risk (eg, prophylactic surgery or magnetic resonance
imaging screening), even in the absence of any other factors.
Moderate-penetrance alleles confer risks of greater than
twofold, corresponding to lifetime risks of 20% in Western
populations, whereas low-penetrance alleles confer smaller
increases in risk (ie, 10% to 20% lifetime risk).
Rare High-Penetrance Alleles
Family-based linkage analysis and positional cloning were
used to identify high-penetrance alleles in BRCA1 and
BRCA2, two tumor-suppressor genes involved in DNA
Figure 1 Genetic loci identiﬁed for breast cancer by risk allele
frequency and risk conferred.
Genetic Susceptibility to Breast Cancerrepair.7,8 Deleterious alleles of these genes are rare (cumu-
lative frequency, approximately 1 in 800 for BRCA1 muta-
tions and 1 in 500 for BRCA2mutations9) and confer a 10- to
30-fold increase in the risk of breast cancer in carriers
compared with noncarriers.10 These alleles also predispose to
other cancer types, including ovarian and prostate cancers.11
Deleterious alleles in other genes conferring a similar risk
to BRCA1 and BRCA2 may exist, but they are likely to be
rare, because approximately 84% of families with four or
more cases of breast cancer diagnosed at younger than 60
years can be accounted for by mutations in BRCA1 or
BRCA2.10 A few high-penetrance alleles have been identi-
ﬁed as part of inherited cancer symptoms, such as TP53
mutations found in Li-Fraumeni cancer syndrome12 and
STK11/LKB1 mutations found in Peutz-Jegher syndrome.13
Rare Moderate-Penetrance Alleles
Moderate-penetrance variants have been found by rese-
quencing candidate genes, such as those interacting with
BRCA1 and BRCA2, or acting in the same DNA repair
pathway. Protein truncating variants in ATM,14 CHEK2,15,16
PALB2,17 and BRIP118 genes have been shown to confer
a twofold to fourfold risk of breast cancer. Other moderate-
penetrance genes have been identiﬁed through linkage
studies in families with rare syndromes involving breast and
other malignancies. Deleterious alleles of PTEN (Cowden
disease)19 and CDH1 (hereditary diffuse gastric cancer)20
confer relative risks of two to eight. It is likely that other
genetic variations in this category exist, but their identiﬁca-
tion will require resequencing in large case-control studies.
The susceptibility alleles previously mentioned are rare
and do not reach a frequency of >1% even when combined,
suggesting a selective disadvantage, possibly as a result of
homozygotes being nonviable or seriously disadvantaged.
Altogether, they account for <25% of the familial risk of
breast cancer.21
Common Low-Penetrance Variation
Susceptibility alleles that are common in the general pop-
ulation (minor allele frequency of >5%) are associated with
a modest increase in breast cancer risk (relative risk of <1.5;
no alleles with a relative risk between 1.5 and 2 have been
identiﬁed). Such alleles are generally identiﬁed by case-
control, association studies. Early association studies using
a candidate gene approach focused on polymorphisms in
genes thought to be relevant to cancer biology through
mechanisms such as cell cycle regulation, apoptosis, and
DNA repair. Many positive associations were reported, but
few have been convincingly replicated.22 The most
convincing reported evidence is for a coding polymorphism
in CASP8, D302H, the minor allele of which has been
associated with a reduced risk of breast cancer.23
During the past 5 years, improvements in genotyping
technology have made genome-wide association studiesThe American Journal of Pathology - ajp.amjpathol.org(GWASs) possible. In GWASs, a few 100,000 variants that
report on the most common variation in the genome are
genotyped, allowing associations to be detected without
prior knowledge of function or location. GWASs have been
extremely successful in identifying susceptibility loci for
many common diseases and phenotypes. To date, 72 breast
cancer susceptibility loci have been identiﬁed through
GWASs and large-scale replication studies.24e36 The asso-
ciated single-nucleotide polymorphisms (SNPs) and the
nearest genes to each of the loci are summarized in Table 1.
These loci, however, explain approximately 14% of the
inherited genetic component of breast cancer. It is likely that
there are many more common alleles with weak effects.
Association of GWAS Loci by Tumor Subtypes
Breast cancer is heterogeneous, and different types of tumors
can vary etiologically, histologically, and clinically.37 More
than 90% of breast tumors that develop in carriers of BRCA1
mutations are estrogen receptor negative (ER),37 whereas
the common breast cancer susceptibility alleles identiﬁed are
more strongly associated with ERþ disease (FGFR2,
MAP3K1, 8q24, 5p12, 11q13, 12q24, and 21q21) and less
strongly, if at all, with ER disease. Some loci, such as 16q12
(TOX3), 12p11 (PTHLH ), and 10q21 (ZNF365), are asso-
ciated with both disease types.26,30,31,38e41 Seven loci with
common susceptibility alleles for ER breast cancer have
been identiﬁed: 6q25 (near ESR1) was ﬁrst identiﬁed in
a GWAS conducted in Chinese women33; 19p13 was initially
identiﬁed as a modiﬁer of BRCA1 breast cancer,25 and 5p12
was identiﬁed through a GWAS in ER and triple-negative
(ER/PR/HER) breast cancer.28 Four loci (1q32,
MDM4; 1q32, LGR6; 2p24, no nearby genes; 16q12, FTO)
were recently identiﬁed after combining three GWASs
comprising 4193 ER-negative breast cancer cases and 35,194
controls.34 Most GWAS loci also modify the penetrance of
breast cancer in BRCA2 carriers, to a similar relative extent,
but only the subset of SNPs associated with ER disease
appear to modify the risk in BRCA1 carriers, consistent with1039
Table 1 List of the 72 Breast Cancer Susceptibility Loci Identiﬁed to Date.
Region SNP Nearest plausible genes Year Per-allele OR P value MAF
1p11 rs11249433 NOTCH2/FCGR1B 2009 1.16 (1.09e1.24) 7  1010 0.39
1p13 rs11552449 TPN22/BCL2L15 2013 1.07 (1.04e1.09) 1.8  108 0.17
1p36 rs616488 PEX14 2013 0.94 (0.92e0.96) 2.0  1010 0.33
1q32 rs4245739 MDM4 2013 1.14 (1.10e1.18) 2.1  1012 0.26
1q32 rs6678914 LGR6 2013 1.10 (1.06e1.13) 1.4  108 0.59
2p24 rs12710696 desert 2013 1.10 (1.06e1.13) 0.36
2q14 rs4849887 None 2013 0.91 (0.88e0.94) 3.7  1011 0.10
2q31 rs2016394 METAP1D 2013 0.95 (0.93e0.97) 1.2  108 0.48
2q31 rs1550623 CDCA7 2013 0.94 (0.92e0.97) 3.0  108 0.16
2q33 rs1045485 CASP8 2007 0.88 (0.84e0.92) 1.1  107 0.13
rs10931936 0.88 (0.82e0.94) 0.26
2q35 rs13387042 IGFBP2, IGFBP5, TPN2 2007 1.20 (1.14e1.26) 1  1013 0.49
2q35 rs16857609 DIRC3 2013 1.08 (1.06e1.10) 1.1  1015 0.26
3p24 rs4973768 SLC4A7/NEK10 2009 1.11 (1.08e1.13) 4.1  1023 0.46
3p24 rs12493607 TGFBR2 2013 1.06 (1.03e1.08) 2.3  108 0.35
3p26 rs6762644 ITPR1/EGOT 2013 1.07 (1.04e1.09) 2.2  1012 0.40
4q24 rs9790517 TET2 2013 1.05 (1.03e1.08) 4.2  108 0.23
4q34 rs6828523 ADAM29 2013 0.90 (0.87e0.92) 3.5  1016 0.13
5p12 rs10941679 MRPS30/HCN1 2008 1.19 (1.13e1.26) 1  1011 0.25
rs9790879 1.10 (1.03e1.17) 0.40
5p15* rs10069690 TERT/CLPTM1L 2011 1.18 (1.13e1.25) 1.0  1010 0.30
5q11 rs889312 MAP3K1/MEIR3 2007 1.13 (1.10e1.16) 1  1015 0.28
5q11 rs10472076 RAB3C 2013 1.05 (1.03e1.07) 2.9  108 0.38
5q11 rs1353747 PDE4D 0.92 (0.89e0.95) 2.5  108 0.10
5q33 rs1432679 EBF1 2013 1.07 (1.05e1.09) 2.0  1014 0.43
6p23 rs204247 RANBP9 2013 1.05 (1.03e1.07) 8.3  109 0.43
6p25 rs11242675 FOXQ1 2013 0.94 (0.92e0.96) 7.1  109 0.39
6q14 rs17530068 None 2012 1.12 (1.08e1.16) 1.1  109 0.22
6q25 rs3757318 ESR1 2009 1.21 (1.13e1.31) 2  1015 0.07
6q25 rs2046210 ESR1 2009 1.11 (1.07e1.16) 3.7  109 0.34
7q35 rs720475 ARHGEF5/NOBOX 2013 0.94 (0.92e0.96) 7.0  1011 0.25
8p12 rs9693444 None 2013 1.07 (1.05e1.09) 9.2  1014 0.32
8q21 rs6472903 None 2013 0.91 (0.89e0.93) 1.7  1017 0.18
8q21 rs2943559 HNF4G 2013 1.13 (1.09e1.17) 5.7  1015 0.07
8q24 rs13281615 MYC 2007 1.08 (1.05e1.11) 5  1012 0.40
8q24 rs1562430 MYC 2010 1.17 (1.10e1.25) 5  1012 0.40
8q24 rs11780156 MIR1208 2013 1.07 (1.04e1.10) 3.4  1011 0.16
9p21 rs1011970 CDKN2A/B 2010 1.09 (1.04e1.14) 2.5  108 0.17
9q31 rs865686 KLF4/RAD23B 2011 0.89 (0.85 0.92) 1.7  1010 0.39
9q31 rs10759243 None 2013 1.06 (1.03e1.08) 1.2  108 0.39
10p12 rs7072776 MLLT10/DNAJC1 2013 1.07 (1.05e1.09) 4.3  1014 0.29
10p12 rs11814448 DNAJC1 2013 1.26 (1.18e1.35) 9.3  1016 0.02
10p15 rs2380205 ANKRD16 2010 0.94 (0.91e0.98) 4.6  107 0.43
10q21 rs10995190 ZNF365 2010 0.86 (0.82e0.91) 5.1  1015 0.15
10q22 rs704010 ZMIZ1 2010 1.07 (1.03e1.11) 3  108 0.39
10q25 rs7904519 TCF7L2 2013 1.06 (1.04e1.08) 3.1  108 0.46
10q26 rs2981582 FGFR2 2007 1.26 (1.23e1.30) 2  1076 0.38
10q26 rs2981579 FGFR2 2010 1.43 (1.35e1.53) 2  1076 0.42
10q26 rs11199914 None 2013 0.95 (0.93e0.97) 1.9  108 0.32
11p15 rs3817198 LSP1/H19 2007 1.07 (1.04e1.11) 1  109 0.30
11p15 rs909116 LSP1/H19 2007 1.17 (1.10e1.24) 1  109 0.30
11q13* rs614367 CCND1/FGFs 2010 1.15 (1.10e1.20) 3.2  1015 0.15
11q13 rs3903072 OVOL1 2013 0.95 (0.93e0.96) 8.6  1012 0.47
11q24 rs11820646 None 2013 0.95 (0.93e0.97) 1.1  109 0.41
12p11 rs10771399 PTHLH 2011 0.79 (0.71e0.87) 4.3  1035 0.10
12p13 rs12422552 None 2013 1.05 (1.03e1.07) 3.7  108 0.26
12q22 rs17356907 NTN4 2013 0.91 (0.89e0.93) 1.8  1022 0.30
(table continues)
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Table 1 (continued )
Region SNP Nearest plausible genes Year Per-allele OR P value MAF
12q24 rs1292011 TBX3/MAPKAP5 2011 0.92 (0.91e0.94) 5.9  1019 0.41
13q13 rs11571833 BRCA2 2013 1.26 (1.14e1.39) 4.9  108 0.01
14q13 rs2236007 PAX9/SLC25A21 2013 0.93 (0.91e0.95) 1.7  1013 0.21
14q24 rs999737 RAD51B 2009 0.94 (0.88e0.99) 2  107 0.24
14q24 rs8009944 RAD51B 2009 0.88 (0.82e0.95) 2  107 0.24
14q24 rs2588809 RAD51L1 2013 1.08 (1.05e1.11) 1.4  1010 0.16
14q32 rs941764 CCDC88C 2013 1.06 (1.04e1.09) 3.7  1010 0.34
16q12 rs12443621 TOX3/LOC643714 2007 1.11 (1.08e1.14) 1  1036 0.46
16q12 rs3803662 TOX3/LOC643714 2010 1.20 (1.16e1.24) 1  1036 0.26
16q12 rs17817449 MIR1972-2-FTO 2013 0.93 (0.91e0.95) 6.4  1014 0.40
16q23 rs13329835 CDYL2 2013 1.08 (1.05e1.10) 2.1  1016 0.22
16q22 rs11075995 FTO 2013 1.07 (1.11e1.15) 4.0  108 0.24
17q23 rs6504950 STXBP4/COX11 2008 0.95 (0.92e0.97) 1.4  108 0.27
18q11 rs527616 None 2013 0.95 (0.93e0.97) 1.6  1010 0.38
18q11 rs1436904 CHST9 2013 0.96 (0.94e0.98) 3.2  108 0.40
19p13 rs8170 MERIT40 2010 1.26 (1.17e1.35) 2.3  109 0.18
19p13 rs2363956 MERIT40 2010 0.84 (0.80e0.89) 5.5  109 0.50
19p13 rs4808801 SSBP4/ISYNA1/ELL 2013 0.93 (0.91e0.95) 4.6  1015 0.35
19q13 rs3760982 KCNN4/ZNF283 2013 1.06 (1.04e1.08) 2.1  1010 0.46
20q11 rs2284378 RALY 2012 1.16 (1.01e1.10) 1.1  108 0.35
21q21 rs2823093 NRIP1 2011 0.94 (0.92e0.96) 1.1  1010 0.27
22q12 rs132390 EMID1/RHBDD3 2013 1.12 (1.07e1.18) 3.1  109 0.04
22q13 rs6001930 MKL1 2013 1.12 (1.09e1.16) 8.8  1019 0.11
MAF, minor allele frequency.
*For each of the 5p15/TERT locus and 11q13/CCND1 locus, three independent SNPs are associated with breast cancer.
Genetic Susceptibility to Breast Cancerthe distinct pathological characteristics of the disease in
BRCA1 carriers.
With the exception of the FGFR2 locus, which also shows
the strongest association with breast cancer, the mechanisms
and the genes behind these associations are largely unknown.
However, knowledge about gene function within the regions
suggests that a complex and diverse range of biological path-
ways are involved in the common susceptibility to breast
carcinogenesis. Almost all of the loci are in regions that contain
genes that could be involved in breast cancer development
(Figure 2), and it is notable that several of these genes havebeen
shown to be somatically mutated in breast tumors (MAP3K1,
TBX3, NOTCH2, MYC, CASP8, CCND1, and TET2).42
However, in almost all cases, there is no direct evidence that
these genes are causally related to the observed susceptibility.
From Association to Causation and Function: A
Major Challenge for Molecular Genetics
There are two key steps to understanding the functional mech-
anisms bywhich the risk-associated variant causes breast cancer
at a susceptibility locus. The ﬁrst is to identify the true causal
variant at the locus, and the second is to identify the molecular
mechanism by which the risk allele could cause cancer.
Fine-Scale Mapping
Fine-scale mapping aims to identify the causal variant(s) at
a susceptibility locus. The set of SNPs genotyped in a GWASThe American Journal of Pathology - ajp.amjpathol.orgare designed to tag commonvariation across the genome. Thus,
most variants found to be associated with disease will be
correlated with multiple other variants in the surrounding
region [called a linkage disequilibrium (LD) block or a haplo-
type block], for which the boundaries are delimited by
recombinationhot spots.Haplotype blocksvary substantially in
size, the number of SNPs, and the LD structure of those SNPs.
Several steps are required to narrow down a locus of
interest and pinpoint the causal variant(s). The ﬁrst step is to
obtain a complete list of all variants in the LD block of
interest. The availability of the 1000 Genomes project
(http://www.1000genomes.org, last accessed July 29, 2013)
has accelerated this process, and resequencing of the region
is usually no longer needed to search for common variants.
Ideally, all of the SNPs correlated with the associated
marker are then genotyped in a large case-control set, and
the strength of association is compared. The variant with the
strongest statistical evidence for association is the strongest
candidate for being the causal variant. However, because of
the high correlation among SNPs within a block, multiple
SNPs may have equally strong evidence and the true causal
variant may not be deﬁnitively identiﬁed. Because the
pattern of LD often differs among populations, case-control
studies from multiple populations (notably populations of
East Asian or African ancestries, in addition to European
ancestry) can assist with the ﬁne mapping, provided that
the same causal variant segregates in each population
(Figure 3). However, complementary approaches are still
likely to be required to identify a single causal variant.1041
Figure 2 Mechanisms that are potentially involved in breast cancer susceptibility. Genes in red represent high- and moderate-penetrance mutations. Genes
in blue are cancer candidates found in/near common breast cancer susceptibility loci. With the exception of FGFR2, MYC, CASP8, and CCND1, it is unclear if
those genes are the ones driving the association. Follow-up of the associated loci and functional analysis will conﬁrm or exclude the involvement of these
genes.
Ghoussaini et alBecause the causative variant is expected to be more
strongly associated with breast cancer risk than other SNPs,
ﬁnding the causal variant in each of the GWAS loci will also
improve the accuracy of disease risk prediction. Bio-
informatic analysis SNPs may have a variety of functional
effects, by either directly altering protein structure (missense
variants or splice site variants) or altering the transcriptional
regulation of nearby genes. In silico bioinformatics analysis
can help identify SNPs more or less likely to have a func-
tional effect.43 For example, SNPs in genomic regions that
are highly conserved between species are more likely to be
functionally important, particularly those in noncoding
regions. Genome data on many species, including 28
vertebrate species, are publicly available to enable such
analyses to be routine. The ENCyclopedia Of DNA Elements
(National Human Genome Research Institute, NIH, http://
www.genome.gov/10005107, last accessed July 29, 2013)
project has recently provided functional annotation across the
human genome [histone modiﬁcation and regulatory
elements, DNA methylation, DNase-hypersensitive sites and
footprints, chromosome-interacting regions, transcription
factor (TF) binding sites, regulatory elements, and coding
and noncoding RNAs], showing that 80% of the noncoding
genome could be functional.44 Putative causal SNPs can be
mapped to see if they lie in speciﬁc functional elements, such
as enhancers, silencers, or TF binding sites.
When the LD block of interest contains several genes, it
may be difﬁcult to predict what gene is being targeted by the
associated variant. Because most associations are thought to1042be regulatory, the target gene may be identiﬁed by evalu-
ating whether the SNP genotype is associated with gene
expression. For example, a gene expression database, GENe
Expression VARiation, in which the expression of genes
was quantiﬁed in immortalized B lymphocytes extracted
from the 270 HapMap individuals of European, Asian, and
African ancestries, has been made publicly available. This
approach may be limited by the size of the association with
expression levels, which may be modest. More important,
expression may be tissue speciﬁc, in which case available
data in, for example, blood will be of limited value.
Emerging data on expression in tumors, through projects
such as The Cancer Genome Atlas (National Cancer Insti-
tute, http://www.cancergenome.nih.gov, last accessed July
29, 2013) and the International Cancer Genome Consortium
Cancer Genome Projects (http://www.icgc.org, last accessed
July 29, 2013), may be more valuable for analysis of genes
expressed in the breast, but ultimately studies in normal
breast tissue may be required.
Functional Experiments
Experiments to determine the functional effect of candidate
causal variants are beyond the scope of this review. Brieﬂy,
if an SNP falls in the noncoding region of the genome
(promoter, enhancer, or intron) and is predicted to affect the
binding of a TF, experiments such as electrophoretic
mobility shift assays can be used to test for a differential
protein binding pattern. Luciferase transfection assays canajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Schematic diagram of the LD pattern in a different pop-
ulation. This diagram illustrates the value of using populations from other
ethnicities to reﬁne the signal of association. Haplotype 1 in population 1
is split into three haplotypes in population 2. In population 1, the causal
variant and the tag SNPs are both in the same haplotype block, in high
correlation with each other, and are hence both associated with the
disease. In population 2, the causal variant is no longer on the same
haplotype as the tag SNP because they were separated by a recombination
event. Therefore, if we were to genotype both SNPs in population 2, the
causal variant will remain associated with the disease but not the tag SNP.
Assuming that the LD structure is different between populations for the
locus of interest, ﬁne mapping in other ethnicities can help to reduce the
number of candidate causal variants.
Genetic Susceptibility to Breast Cancerbe used to measure the activity of a promoter or the
expression of target genes. Chromatin immunoprecipitation
can be used to establish whether the site of a candidate
causal variant is occupied by a TF in vivo. This approach
was recently used to determine the SNPs that are likely to
have a functional effect in FGFR2.45 Chromosome confor-
mation capture can be used to test long-range interactions
that inﬂuence gene expression (eg, between a regulatory
element containing the causal SNP and the promoter of the
suspected targeted gene). This technique was used for the
ﬁne mapping of the 11q13 locus, where the enhancer and
silencer in which the causal variants lie were found to
interact with the promoter and terminator of the CCND1
gene.46
In summary, a combination of genetic epidemiological
characteristics, in silico bioinformatics, and functional
experiments may enable the causal variant (or variants) to be
identiﬁed with some certainty.
Fine Mapping in Breast Cancer
To date, only four of the 72 known breast cancer suscepti-
bility loci have been thoroughly ﬁne mapped in European,
Asian, and African American populations.26,45e49 In addi-
tion, 19 of the breast cancer susceptibility loci have been
ﬁne mapped in African Americans.50
FGFR2 Locus
Two variants in intron 2 of FGFR2 on the 10q26 locus were
found to be associated with breast cancer in two different
studies.26,29 Fine-scale mapping in Europeans, Asians, and
African Americans identiﬁed eight SNPs as the most likely
candidates for being the causal variant.26,47 The most
strongly associated SNP, rs2981578, lies in an open chro-
matin conformation region, where DNA is highly conserved
among mammalian species and was found to mediate
differential TF binding, leading to an increase in FGFR2
expression levels.47 The same SNP was associated with
increased FGFR2 signaling activity in stromal ﬁbroblasts.51
These data altogether suggest that rs2981578 is likely to be
functional. Another correlated SNP, rs7895676, was also
found to increase FGFR2 expression.47 With the availability
of a more complete catalog of common variants released by
the 1000 Genome project and ﬁne mapping in larger case-
control studies, it is possible that additional causal vari-
ant(s) may be identiﬁed.
TOX3 Locus
The second strongest GWAS locus lies in a region on
chromosome 16q12 containing TOX3 (formerly called
TNRC9) and LOC643714.26,52 The number of candidate
causal variants was reduced to 13 using data from European
and Asian studies, with eight clustering in a highly
conserved region of open chromatin conformation located inThe American Journal of Pathology - ajp.amjpathol.orgthe intergenic region.26,52 Based on these data, it was
impossible to discriminate which one of the 13 was the
causal variant. In African American studies, these variants
had completely opposite effects, suggesting the existence of
an additional risk variant, not present in Europeans and
Asians, although this hypothesis requires conﬁrmation.52
The expression of TOX3 did not vary by the genotypes of
the original risk variant, rs3803662, in normal and tumor
breast samples.52 Long et al53 found the strongest associa-
tion with one of the 13 variants, rs4784227, in Asian and
European case-control studies, and demonstrated that this
variant is functional in luciferase and electrophoretic
mobility shift assays. However, unlike the variants previ-
ously mentioned, it lies in a region of closed chromatin,
emphasizing the difﬁculty in interpreting functional exper-
iments in this context.53 More recently, rs478227 was
associated with increased FOXA1 binding and a repressive
effect on TOX3.54
CCND1 Locus (11q13)
The 11q13 locus (rs614367) was among the loci with the
strongest association with breast cancer.32 Extensive ﬁne-
scale mapping of this locus using 4405 genotyped and
imputed variants was performed in 89,050 European
subjects from the Breast Cancer Association Consortium
(BCAC).46 Three independent association signals were
detected and were strictly conﬁned to ERþ tumors;
rs554219, in the strongest peak, lies in an enhancer element,
increases breast cancer risk, induces differential binding of
a TF, reduces the enhancer activity, and is associated with
a decrease in cyclin D1 (CCND1) levels in breast tumors. A
second, independent SNP in the same peak, rs78540526,
lies in the same enhancer element and also appears to be
functional. A third SNP, rs75915166, generates a GATA3
binding site within a silencer element. A long-range1043
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ﬁed between the enhancer and silencer elements and with
CCND1. These associations were replicated in Asian pop-
ulations despite their low frequency (<2%), providing
further support that these SNPs may be causative. The effect
sizes of those newly identiﬁed SNPs are larger than any
previously reported breast cancer GWAS loci.46
TERT Locus (5p15)
Fine-scale mapping of the TERT locus was performed in
approximately 103,000 breast cancer cases and controls
(European, Asian, and African American ancestries) from
BCAC, approximately 12,000 BRCA1 carriers, and approx-
imately 40,000 ovarian cancer cases and their matching
controls.49 Three independent association signals were
identiﬁed. SNPs in peak 1 (TERT promoter) were associated
with telomere length, ERþ and ER breast cancer, and breast
cancer in BRCA1 carriers. SNPs in peak 2 (introns 2 to 4)
were associated with telomere length and all breast and
ovarian cancers. SNPs in peak 3 (introns 2 to 4) were asso-
ciated with ER breast cancer, breast cancer in BRCA1
carriers, and ovarian cancer, but not with telomere length.
The ﬁndings provide evidence for genetic control of telomere
length by common variants across TERT. However, only the
direction of the ﬁndings in peak 1 supports the hypothesis
that shorter telomere length increases the risk of breast
cancer, suggesting that most of cancer associations identiﬁed
in the TERT locus are likely to be mediated through an
alternative mechanism involving the TERT gene.49
Biological Characteristics of Known
Low-Penetrance Breast Cancer Loci: Insights
into Genes and Pathways
For most of the known susceptibility loci, neither the causal
variant nor the gene through which the functional effects of
that variant are mediated is known. Nevertheless, by
considering the known functions of all of the genes near
a susceptibility locus, which are thus candidates for being
the functionally relevant gene, some patterns begin to
emerge.
Mammary Gland Development
Three of the breast cancer susceptibility loci are in regions
with genes that are candidates because they are involved in
mammary gland development: FGFR2 at 10q26, PTHLH at
12p11, and TBX3 (T-BoX3) at 12q24. FGFR2, a tyrosine
kinase receptor, plays a key role in normal mammary gland
development and stem cell function.55 It is overexpressed and
ampliﬁed in 5% to 10% of breast tumors. Several missense
somatic mutations, inducing FGFR2 overexpression, have
been found in multiple cancers.56,57 PTHLH, an oncoprotein
expressed in approximately 60% of breast tumors, plays1044a key role in lactation.58 It has also been suggested that
patients with PTHLH-positive breast carcinoma are more
likely to develop bone metastasis.58 TBX3 is a downstream
target of the WNT/b-catenin pathway (playing a key role in
stem cell regulation and cell differentiation and prolifera-
tion), is ampliﬁed and overexpressed in several cancers,
including breast cancer, and is found at high levels in plasma
from breast cancer patients.59 Germ-line mutations that
disrupt TBX3 are responsible for Ulnar-Mammary syndrome,
a condition characterized by defects of several organs,
including the mammary glands and the heart.60 Expansion of
breast cancer stem cells by estrogen has been found to be
mediated by FGF/FGFR/TBX3 pathways.59
DNA Repair Pathway
DNA repair processes play a key role in the maintenance of
genomic integrity. Five susceptibility loci are near genes
involved in the DNA repair pathway: RAD51B at 14q24,
RAD23B at 9q31, MUS81 at 11q13, SSBP4 at 14q13, and
BABAM1 at 19p13. RAD51B is involved in the homologous
recombination repair pathway. Overexpression of this gene
causes cell cycle G1 delay and cell apoptosis,
61 and copy
number variation at 14q24 has been observed consistently in
families with Li-Fraumeni syndrome.62 RAD23B also has
a key function in recognizing DNA lesions and in the nucle-
otide excision repair pathway, as well as in targeting ubiq-
uitylated proteins for proteasomal degradation.63 MUS81 is
important in DNA repair mechanisms and in maintaining
genome stability.64 SSBP4 is also involved in DNA repair and
recombination and acts as a tumor-suppressor gene.65
BABAM1 interacts with BRCA1 in the DNA repair process
and enforces the BRCA1-dependent DNA damage response.66
Cell Cycle, Differentiation, and Apoptosis
Cell division, differentiation, and apoptosis are similar in
both normal and tumor cells, except that these processes are
aberrantly regulated in cancer, leading the cancer cell and its
progeny into uncontrolled expansion and invasion. Most
breast cancer susceptibility loci contain genes with a central
function in these pathways. These include MDM4 at 1q32,
CDKN2A and CDKN2B at 9p21, MAP3K1 at 5q11,
MRPS30 at 5p12, MYC at 8q24, TCF7L2 at 10q25, MAP-
KAP/MK5 at 12q24, NOTCH2 at 1p11, CCND1 and FGFs
at 11q13, and KREMEN1 at 22q12. MDM4 is an oncogene
that represses the transcription of TP53 and TP73 and
therefore plays a key role in cell cycle regulation and
apoptosis.67 CDKN2A and CDKN2B are tumor-suppressor
genes that lie adjacent to each other. The p16 protein
encoded by CDKN2A plays an important role in cell cycle
arrest, and its inactivation is a crucial event in the devel-
opment of several types of human tumors.68 CDKN2B is
another cell growth regulator that controls cell cycle G1
progression. Its expression is dramatically induced by
transforming growth factor-b, suggesting its involvement inajp.amjpathol.org - The American Journal of Pathology
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tion.69,70 MAP3K1 encodes a component of the mitogen-
activated protein kinase (MAPK) signaling pathway,
known for its key role in cell differentiation, proliferation,
and apoptosis.71 MAP3K1 regulates cell migration and
survival, as well as immune system function. MAP3K1-
deﬁcient retinas exhibit increased proliferation and
apoptosis in mice.72 MRPS30 (programed cell death protein
9/PDCP9) is a key component of the apoptotic signals in
cells.73 MYC is a proto-oncogene that drives several mito-
genic signals through activation of the MAPK/extracellular
signal-regulated kinase pathway.74 MYC is overexpressed
in different tumors, including breast and prostate cancers,74
and reducing its expression levels using RNA interference
inhibits tumor growth both in vivo and in vitro.75 The
TCF7L2 is a proto-oncogene, an important component of
the WNT pathway, and is well known for its association
with type 2 diabetes.76 The MAPKAPKs have a pivotal role
in the cell mitogenic processes and survival and are directly
regulated by MAPKs.77 MK5/MAPKAP5 was found to
regulate the translation of MYC and vice versa by a negative
feedback loop.78 NOTCH2 belongs to a family of trans-
membrane receptors and plays a key role in cell differenti-
ation, proliferation, and apoptosis.79 Decreases in NOTCH2
expression are associated with increasing grade of human
breast cancer,80 and its signaling is required for anti-tumor
immunity in vivo.81 CCND1 is a key cell cycle regulator,
and its ampliﬁcation and overexpression were documented
in a variety of tumors.82 FGFs have diverse roles in regu-
lating cell proliferation, migration, and differentiation, and
they play a role in cancer pathogenesis.83 KREMEN1
suppresses the WNT/b-catenin pathway, and its expression
is low or absent in tumor cells compared with normal
tissues. Lack of KREMEN1 and therefore activation of the
WNT/b-catenin pathway is likely to be one of the mecha-
nisms by which tumorigenesis is enhanced.84
Of these regions, only 8q24 has been the focus of
multiple functional experiments. Several independent loci,
clustered in a region with no genes a few hundred kb
upstream and downstream of MYC, have been found to be
associated with an increased risk of prostate, breast, colo-
rectal, ovarian, glioblastoma, and bladder cancers, as well as
lymphocytic leukemia (National Humane Genome Research
Institute, NIH, http://www.genome.gov/gwastudies, last
accessed July 29, 2013). Functional assessment both in vivo
and in vitro identiﬁed enhancer elements in each of the loci,
including mammary and prostate enhancers that interact
physically with the MYC and PVT-1 promoters through
a long-range chromatin loop and regulate its expression
levels.85e87
Growth Factors and Tumor Aggressiveness
Although departure from tissue homeostasis and initiation of
cancer are mainly initiated by oncogenic mutations, growth
factors play a major role in the subsequent steps of tumorThe American Journal of Pathology - ajp.amjpathol.orgprogression, particularly clonal expansion, invasiveness,
and colonization of distant organs. Several genes near the
most recently identiﬁed loci encode a growth factor (NTN4
at 12q22) or are involved in tumor aggressiveness and
metastasis (PTH1R at 3p21), FOXQ1 at 6p25, ARHGEF5 at
7q35, PAX9 at 14q13, and MKL1 at 22q13. NTN4 encodes
a growth factor crucial for the regulation of tumor growth.
High expression levels of NTN4 were detected in ERþ
breast cancer but not in ER, and its use was suggested as
a prognosis marker.88 PTH1R is the receptor of PTHLH
(also identiﬁed in a GWAS). Up-regulation of PTH1R was
found in patients with invasive breast ductal carcinoma.
Silencing PTH1R induced suppression of cell prolifera-
tion.89 Forkhead TF (FOXQ1) plays a key role in regulating
epithelial-mesenchymal transition (EMT; crucial for
metastasis) in breast cancer cells. Its expression is correlated
with high-grade breast cancers and is associated with poor
prognosis. Silencing FOXQ1 reversed EMT in invasive
human breast cancer cell lines and decreased their inva-
siveness. Conversely, overexpression of FOXQ1 in human
mammary epithelial cells induced an EMT and the acqui-
sition of resistance to apoptosis after chemotherapy.90
ARHGEF5 is an oncogene and plays a pivotal role in
cancer development and breast metastasis through activation
of the ARHGEF5/TIM pathway.91 PAX9 encodes a TF that
regulates cell proliferation, invasion, and resistance to
apoptosis.92 MLK1 is also important in cell invasion and
metastasis, particularly in breast carcinomas.93
ER Pathway
Estrogen plays a key role in growth and in the maintenance
of reproductive functions. Two breast cancer susceptibility
loci are near genes with pivotal roles in this pathway. One at
6q25 is close to ESR1 and the other, at 21q21, is close to
NRIP1/RIP140. ESR1 encodes the ERa protein, which is
activated by bound estrogen. NRIP1 is a cofactor of ERa
and can inhibit its mitogenic effects. This gene plays an
important role in the regulation of breast cancer cell growth,
notably in ER-positive breast tumors.94
Telomere Length
Telomeres are regions of repetitive nucleotides at the end of
chromosomes. They are crucial in maintaining genomic
stability by protecting chromosomes from degradation,
recombination, and end-to-end fusion.95 Human telomeres
tend to progressively shorten with each cell division, and
this shortening process is associated with ageing and
increased risk of cancer.96 One of the identiﬁed breast
cancer susceptibility loci lies at 5p15 and is near TERT,
which encodes telomerase reverse transcriptase, the catalytic
subunit of telomerase.28 Abnormal expression of TERT has
been reported in several types of cancer, and the region is
frequently ampliﬁed in many types of cancer, such as lung
and cervical cancers.97,981045
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Many genes near the known susceptibility loci are either of
unknown function or have functions that do not have a clear
connection to breast cancer development (a notable example
being the TOX3 locus). These genes could simply not be the
ones being targeted, but alternatively might be involved in
susceptibility through a previously unsuspected mechanism.
Future functional analysis should shed some light on the
causal variants within each of these loci and the mechanisms
by which they are driving the association.Common Pathways for Multiple Phenotypes
Although most breast cancer susceptibility loci are disease
speciﬁc, at least 17 loci (at 1q32, 2p24, 2q31, 4q24, 5p12,
5p15, 6q25, 8q24, 9p21, 9q31, 10p12, 10q26, 11p15,
11q13, 12q24, 14q24, and 19p13) occur in regions associ-
ated with other cancers and complex diseases/phenotypes,
suggesting a shared mechanism in disease development
(Figure 4). Four of these have been intensively discussed.
The 5p15 region containing TERT is also associated with
glioma, basal cell carcinoma, and lung and pancreatic
cancers (http://www.genome.gov/gwastudies). The 8q24
region is associated with at least six cancers and one of the
loci, rs6983267, has a pleiotropic effect on prostate, colo-
rectal, and possibly ovarian cancers (http://www.genome.
gov/gwastudies). The 9p21 region containing the two
tumor-suppressor genes, CDKN2A and CDKN2B, isFigure 4 Location of the common breast cancer susceptibility loci together
4q24, 5p12, 5p15, 6q25, 8q24, 9p21, 9q31, 10p12, 10q26, 11p15, 11q13, 12q
cancers.
1046associated with at least seven cancers (breast and pancreatic
cancers, lymphoblastic leukemia, melanoma, glioma, basal
cell carcinoma, and nasopharyngeal carcinoma), myocardial
infarction, type 2 diabetes, intracranial aneurysm, cutaneous
nevi, and sporadic amyotrophic lateral sclerosis (http://
www.genome.gov/gwastudies). The 11q13 region contains
CCND1 and several FGFs and is associated with breast,
prostate, and renal cancers (http://www.genome.gov/
gwastudies. The nearest genes to the 12q24 region are
TBX3, important for mammary gland development, and
MAPKAP, a component of the MAPK pathway that inter-
acts with MYC. SNPs in this region are associated with
breast cancer, squamous esophageal carcinoma, liver
adenoma, renal cell carcinoma, heart diseases, type 1 dia-
betes, blood pressure, and prostate speciﬁc antigen levels
(http://www.genome.gov/gwastudies).
Clinical Implications
Although the clinical utility of testing for high-penetrance
mutations such as BRCA1 and BRCA2, is well established,
the potential clinical use of polygenic prediction for breast
cancer is extensively debated.99e102 Taken separately, the
SNP associations are too weak to be useful on an individual
basis. However, because their effects seem to combine
multiplicatively, there is potential for the predictive power
to improve substantially as more variants are found.101 It
has been argued that polygenic risk proﬁles have limited
discrimination for breast cancer, but because the clinicalwith the most plausible nearby genes. At least 17 loci (1q32, 2p24, 2q31,
24, 14q24, and 19p13) are associated with breast, prostate, and ovarian
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discrimination, these should be further evaluated in the
context of risk stratiﬁcation after combining other risk
factors, such as lifestyle elements and family history.
In a recent study, Pashayan et al103 showed that person-
alized screening based on age and polygenic risk factors (18
common low-penetrance loci) is more efﬁcient than a stan-
dard approach based solely on age. Personalized screening
could reduce the number of people eligible for screening by
24% while detecting most cancers (86%) compared with
a program based on age alone.103 Individual risk stratiﬁca-
tion would increase the efﬁciency of the screening program,
by intensifying screening in high-risk individuals and
sparing unnecessary and even potentially harmful screening
in those with lower risk levels. This increase in efﬁciency
would be even greater for risk stratiﬁcation based on the 72
loci identiﬁed.104
Future Directions
Whole Genome Resequencing
The emerging results from GWASs suggest that a substan-
tial fraction, perhaps the majority, of the familial risk of
breast cancer can be explained by common variants, most of
which are yet to be identiﬁed. It is highly likely that rarer,
higher-risk alleles (such as risk alleles of PALB2) also
remain to be identiﬁed. Unraveling the full architecture of
breast cancer susceptibility will therefore require a compre-
hensive search for rarer variants. Technological advances
over the past few years have rendered whole-exome or
whole-genome resequencing of large cohorts of cases and
controls increasingly more practical.
Consortia and Collaborations
Studies with large sample sizes are critical to enhance
power, achieve genome-wide signiﬁcance levels, and yield
additional insights in terms of replication of the results, new
genetic discoveries, and key biological ﬁndings.
The past few years witnessed the formation of multiple
international consortia and substantial widespread collabo-
rations of many multidisciplinary investigators, including
epidemiologists, clinicians, statisticians, bioinformaticians,
and biologists. Groups with their individual case-control sets
joined efforts to increase sample size through meta-analysis,
and these collaborations resulted in an explosion of new
associations. One of the most successful examples in cancer
is the Collaborative Oncological Gene-Environment Study,
a collaborative project funded by the European Commission,
which combined data from four different consortia: BCAC,
Prostate Cancer Association Group to Investigate Cancer
Associated Alterations in the Genome, the Ovarian Cancer
Association Consortium, and the Consortium of Investigators
of Modiﬁers of BRCA1/2. This collaboration has developed
a genotyping array of approximately 200,000 SNPs that hasThe American Journal of Pathology - ajp.amjpathol.orgbeen used to genotype in approximately 200,000 cases with
breast, prostate, and ovarian cancers and approximately
200,000 controls from around the world. Results from this
project identiﬁed 74 novel breast, prostate, and ovarian
cancer loci (41 of which are for breast cancer), nearly
doubling the number of the previously established ones. In
addition, those results provided an accurate assessment of the
risk related to each locus and will offer a comprehensive ﬁne
mapping of the known loci. It will also be possible to evaluate
genetic associations with disease survival, clinical outcome,
and tumor subsets and to evaluate the combined effect of
genetic variants and lifestyle risk factors on disease risk.
More ﬁndings emerging from this project should add greatly
to our understanding of the genetic architecture of breast and
other cancers.GWASs in Other Populations
Breast cancer GWASs have primarily been conducted in
women of European descent, with the exception of one study
performed in Chinese women, which indicated important
differences in the pattern of genetic loci between ethnicities.
These may result from differences in allele frequencies,
patterns of LD, or interactions with genetic background or
lifestyle risk factors. Further GWASs in non-European
populations should therefore be extremely fruitful.Conclusions
In the future, more breast cancer susceptibility alleles are
likely to be identiﬁed, and these should, in turn, lead to
further functional studies and expand our understanding of
the underlying biological characteristics of breast cancer. The
candidate genes in susceptibility regions identiﬁed thus far
appear to cluster into a few biological pathways: mammary
gland development, DNA repair, cell cycle control, and
estrogen receptor signaling. Genes with unknown function at
these loci will need further work, but their characterization
might reveal unexpected and important insights into cancer
biology. Loci that are associated with breast cancer and other
cancers and traits will be important in revealing biological
mechanisms that connect pathways and diseases. In addition
to the common variants, rare genetic variations identiﬁed
through whole-exome and whole-genome sequencing strat-
egies will likely expand the catalog of breast cancer
susceptibility variations. Further studies to examine struc-
tural variation and epigenomics may also uncover more
susceptibility loci. Integration of the germ-line susceptibility
data with emerging somatic sequence data may be important
to both provide a more comprehensive analysis of suscepti-
bility by disease subtype and interpret better the underlying
biological characteristics. Finally, large-scale population
studies (preferably prospective) will be required to deﬁne the
combined effects of common and rare variants, and lifestyle
and other risk factors, on disease risk. This should lead to1047
Ghoussaini et almore rational strategies of disease prevention, while the
knowledge of breast cancer etiology gained through the
functional understanding of disease susceptibility may lead
to novel therapeutic approaches for breast cancer patients.Acknowledgments
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